Trial reportJournal of the American Society of Nephrology : JASN2015
HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients.
Trial report in Journal of the American Society of Nephrology : JASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 51 citations in OpenAlex.
- Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- Prognostic Value of Inflammatory Indices and the Advanced Lung Cancer Inflammation Index (ALI) for Survival Outcomes in Hemodialysis Patients.Medicina (Kaunas, Lithuania) · 2026Article
- A journey through the molecular networks of endomyocardial biopsies to explore ATTR and ALiScience · 2026Article
- Apolipoproteins in Chronic Kidney Disease and Kidney Transplant: A Long Unfinished Story.International journal of molecular sciences · 2025Review
- Lipoprotein Subfractions Predict All-cause and Cardiovascular Mortality in CKD Patients Undergoing Hemodialysis: A Prospective Cohort Study Based on NMR Metabolomics.Phenomics (Cham, Switzerland) · 2025Article
- Mass Spectrometry-Based Spatial Multiomics Revealed Bioaccumulation Preference and Region-Specific Responses of PFOS in Mice Cardiac Tissue.Environmental science & technology · 2025Article
- High density lipoprotein particle size and function associate with new cardiovascular events in patients with chronic kidney disease.PloS one · 2025Article
- Association of Small HDL Subclasses with Mortality Risk in Chronic Kidney Disease.Antioxidants (Basel, Switzerland) · 2024Article
- Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview.Diabetes & metabolism journal · 2023Review
- The Roles of Fatty Acids and Apolipoproteins in the Kidneys.Metabolites · 2022Review
- Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation.Life (Basel, Switzerland) · 2021Review
- Association of proportion of the HDL-cholesterol subclasses HDL-2b and HDL-3 and macrovascular events among patients undergoing hemodialysis.Scientific reports · 2021Article
- Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease.Biomolecules · 2020Review
- Gadofullerene inhibits the degradation of apolipoprotein B100 and boosts triglyceride transport for reversing hepatic steatosis.Science advances · 2020Article
- The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease.International journal of molecular sciences · 2020Review
- Lipid profiles and risk of major adverse cardiovascular events in CKD and diabetes: A nationwide population-based study.PloS one · 2020Article
- Kidney as modulator and target of "good/bad" HDL.Pediatric nephrology (Berlin, Germany) · 2019Review
- Serum Apolipoprotein B and A1 Concentrations Predict Late-Onset Posttransplant Diabetes Mellitus in Prevalent Adult Kidney Transplant Recipients.Canadian journal of kidney health and disease · 2019Article
- Lipid management in patients with chronic kidney disease.Nature reviews. Nephrology · 2018 · on this mapReview
- Propensity Score-Matched Analysis of the Survival Benefit from Kidney Transplantation in Patients with End-Stage Renal Disease.Journal of clinical medicine · 2018Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High concentrations of HDL cholesterol are considered to indicate efficient reverse cholesterol transport and to protect from atherosclerosis. However, HDL has been suggested to be dysfunctional in ESRD. Hence, our main objective was to investigate the effect of HDL cholesterol on outcomes in maintenance hemodialysis patients with diabetes. Moreover, we investigated the associations between the major protein components of HDL (apoA1, apoA2, and apoC3) and end points. We performed an exploratory, post hoc analysis with 1255 participants (677 men and 578 women) of the German Diabetes Dialysis study. The mean age was 66.3 years and the mean body mass index was 28.0 kg/m(2). The primary end point was a composite of cardiac death, myocardial infarction, and stroke. The secondary end point included all-cause mortality. The mean duration of follow-up was 3.9 years. A total of 31.3% of the study participants reached the primary end point and 49.1% died from any cause. HDL cholesterol and apoA1 and apoC3 quartiles were not related to end points. However, there was a trend toward an inverse association between apoA2 and all-cause mortality. The hazard ratio for death from any cause in the fourth quartile compared with the first quartile of apoA2 was 0.63 (95% confidence interval, 0.40 to 0.89). The lack of an association between HDL cholesterol and cardiovascular risk may support the concept of dysfunctional HDL in hemodialysis. The possible beneficial effect of apoA2 on survival requires confirmation in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.